Journal of Clinical Immunology

, 25:592

Molecular Aspects of Regulation of Collagen Gene Expression in Fibrosis

  • Rashpal K. Bhogal
  • Cristina M. Stoica
  • Tracy L. McGaha
  • Constantin A. Bona


Fibrosis, the hyper-accumulation of scar tissue, is characterized by the overproduction and deposition of type I and III collagen by fibroblasts and is the one of the main pathologic outcomes of the autoimmune disorder scleroderma. While the causes of fibrosis in scleroderma are unknown, cytokines such as TGF-β, IL-4 and IL-13, play a crucial role in the stimulation of collagen production have been implicated in the disease process. In fibroblasts stimulation of collagen production by these cytokines is dependent on the Smad and STAT6 signaling pathways induced by TGF-β and IL-4, IL-13 respectively. Furthermore, mounting evidence suggest cytokine crosstalk is relevant in the sclerotic process. Our laboratory demonstrated an increase in TGF-β1 gene transcription from fibroblasts stimulated with IL-4. In addition, TSK/+ mice lacking the IL-4α receptor show impaired transcription of the TGF-β1 gene and did not display fibrosis. Likewise, it appears that STAT6 plays a role in fibroblast TGF-β1 transcription after IL-4 or IL-13 stimulation. These findings suggest that an epistatic interaction between IL-4 and TGF-β may exist which is crucial for pathologic sclerotic activity.

Key Words

Fibrosis scleroderma pro-fibrogenic cytokines fibroblasts collagen 


  1. 1.
    Aumailley M, Gayraud B: Structure and biological activity of the extracellular matrix. J Mol Med 76:253–265, 1998PubMedCrossRefGoogle Scholar
  2. 2.
    Trojanowska M, LeRoy EC, Eckes B, Krieg T: Pathogenesis of fibrosis: Type 1 collagen and the skin. J Mol Med 76:266–274, 1998PubMedCrossRefGoogle Scholar
  3. 3.
    Aszodi A, Pfeifer A, Wendel M, Hiripi L, Fassler R: Mouse models for extracellular matrix diseases. J Mol Med 76:238–252, 1988Google Scholar
  4. 4.
    Gelse K, Poschl E, Aigner T: Collagens—structure, function, and biosynthesis. Adv Drug Deliv Rev 55:1531–1546, 2003PubMedCrossRefGoogle Scholar
  5. 5.
    Clark RA, Nielsen LD, Welch MP, McPherson JM: Collagen matrices attenuate the collagen-synthetic response of cultured fibroblasts to TGF-beta. J Cell Sci 108(Pt 3):1251–1261, 1995PubMedGoogle Scholar
  6. 6.
    Singer AJ, Clark RA: Cutaneous wound healing. N Engl J Med 341:738–746, 1999PubMedCrossRefGoogle Scholar
  7. 7.
    Mignatti P: Extracellular matrix remodeling by metalloproteinases and plasminogen activators. Kidney Int Suppl 49:S12–S14, 1995PubMedGoogle Scholar
  8. 8.
    Babu M, Diegelmann R, Oliver N: Keloid fibroblasts exhibit an altered response to TGF-beta. J Invest Dermatol 99:650–655, 1992PubMedCrossRefGoogle Scholar
  9. 9.
    Oriente A, Fedarko NS, Pacocha SE, Huang SK, Lichtenstein LM, Essayan DM: Interleukin-13 modulates collagen homeostasis in human skin and keloid fibroblasts. J Pharmacol Exp Ther 292:988–994, 2000PubMedGoogle Scholar
  10. 10.
    Hasegawa M, Fujimoto M, Kikuchi K, Takehara K: Elevated serum tumor necrosis factor-alpha levels in patients with systemic sclerosis: Association with pulmonary fibrosis. J Rheumatol 24:663–665, 1997PubMedGoogle Scholar
  11. 11.
    Gillery P, Fertin C, Nicolas JF, Chastang F, Kalis B, Banchereau J, Maquart FX: Interleukin-4 stimulates collagen gene expression in human fibroblast monolayer cultures. Potential role in fibrosis. FEBS Lett 302:231–234, 1992PubMedCrossRefGoogle Scholar
  12. 12.
    Salmon-Ehr V, Serpier H, Nawrocki B, Gillery P, Clavel C, Kalis B, Birembaut P, Maquart FX: Expression of interleukin-4 in scleroderma skin specimens and scleroderma fibroblast cultures. Potential role in fibrosis. Arch Dermatol 132:802–806, 1996Google Scholar
  13. 13.
    Postlethwaite AE, Holness MA, Katai H, Raghow R: Human fibroblasts synthesize elevated levels of extracellular matrix proteins in response to interleukin 4. J Clin Invest 90:1479–1485, 1992PubMedCrossRefGoogle Scholar
  14. 14.
    McGaha TL, Bona CA: Role of profibrogenic cytokines secreted by T cells in fibrotic processes in scleroderma. Autoimmun Rev 1:174–181, 2002PubMedCrossRefGoogle Scholar
  15. 15.
    Simms RW, Korn JH: Cytokine directed therapy in scleroderma: Rationale, current status, and the future. Curr Opin Rheumatol 14:717–722, 2002PubMedCrossRefGoogle Scholar
  16. 16.
    Bona C, Rothfield N: Autoantibodies in scleroderma and tightskin mice. Curr Opin Immunol 6:931–937, 1994PubMedCrossRefGoogle Scholar
  17. 17.
    Bona C: Anti-fibrillin autoantibodies in scleroderma and mixed connective tissue disease. In K. Conrad, R-L Humbel, M Meurer, et al. (eds). Autoantigens and Autoantibodies: Diagnostic Tools and Clues to Understanding Autoimmunity. Dresden, 2000, pp. 637–647Google Scholar
  18. 18.
    Green MC, Sweet HO, Bunker LE: Tight-skin, a new mutation of the mouse causing excessive growth of connective tissue and skeleton. Am J Pathol 82:493–512, 1976PubMedGoogle Scholar
  19. 19.
    Rossi GA, Hunninghake GW, Gadek JE, Szapiel SV, Kawanami O, Ferrans VJ, Crystal RG: Hereditary emphysema in the tight-skin mouse. Evaluation of pathogenesis. Am Rev Respir Dis 129:850–855, 1984Google Scholar
  20. 20.
    Osborn TG, Bashey RI, Moore TL, Fischer VW: Collagenous abnormalities in the heart of the tight-skin mouse. J Mol Cell Cardiol 19:581–587, 1987PubMedCrossRefGoogle Scholar
  21. 21.
    Murai C, Saito S, Kasturi KN, Bona CA: Spontaneous occurrence of anti-fibrillin-1 autoantibodies in tight-skin mice. Autoimmunity 28:151–155, 1998PubMedCrossRefGoogle Scholar
  22. 22.
    Siracusa LD, McGrath R, Ma Q, Moskow JJ, Manne J, Christner PJ, Buchberg AM, Jimenez SA: A tandem duplication within the fibrillin 1 gene is associated with the mouse tight skin mutation. Genome Res 6:300–313, 1996PubMedCrossRefGoogle Scholar
  23. 23.
    Bona CA, Murai C, Casares S, Kasturi K, Nishimura H, Honjo T, Matsuda F: Structure of the mutant fibrillin-1 gene in the tight skin (TSK) mouse. DNA Res 4:267–271, 1997PubMedCrossRefGoogle Scholar
  24. 24.
    Saito S, Kasturi K, Bona C: Genetic and immunologic features associated with scleroderma-like syndrome of TSK mice. Curr Rheumatol Rep 1:34–37, 1999PubMedCrossRefGoogle Scholar
  25. 25.
    Saito S, Nishimura H, Phelps RG, Wolf I, Suzuki M, Honjo T, Bona C: Induction of skin fibrosis in mice expressing a mutated fibrillin-1 gene. Mol Med 6:825–836, 2000PubMedGoogle Scholar
  26. 26.
    Lemaire R, Farina G, Kissin E, Shipley JM, Bona C, Korn JH, Lafyatis R: Mutant fibrillin 1 from tight skin mice increases extracellular matrix incorporation of microfibril-associated glycoprotein 2 and type I collagen. Arthritis Rheum 50:915–926, 2004PubMedCrossRefGoogle Scholar
  27. 27.
    Assoian RK, Komoriya A, Meyers CA, Miller DM, Sporn MB: Transforming growth factor-beta in human platelets. Identification of a major storage site, purification, and characterization. J Biol Chem 258:7155–7160, 1983Google Scholar
  28. 28.
    Inobe J, Slavin AJ, Komagata Y, Chen Y, Liu L, Weiner HL: IL-4 is a differentiation factor for transforming growth factor-beta secreting Th3 cells and oral administration of IL-4 enhances oral tolerance in experimental allergic encephalomyelitis. Eur J Immunol 28:2780–2790, 1998PubMedCrossRefGoogle Scholar
  29. 29.
    Letterio JJ, Roberts AB: Regulation of immune responses by TGF-beta. Annu Rev Immunol 16:137–161, 1998PubMedCrossRefGoogle Scholar
  30. 30.
    Cheifetz S, Weatherbee JA, Tsang ML, Anderson JK, Mole JE, Lucas R, Massague J: The transforming growth factor-beta system, a complex pattern of cross-reactive ligands and receptors. Cell 48:409–415, 1987PubMedCrossRefGoogle Scholar
  31. 31.
    Massague J: TGF-beta signal transduction. Annu Rev Biochem 67:753–791, 1998PubMedCrossRefGoogle Scholar
  32. 32.
    Roberts AB: TGF-beta signaling from receptors to the nucleus. Microbes Infect 1:1265–1273, 1999PubMedCrossRefGoogle Scholar
  33. 33.
    Huse M, Chen YG, Massague J, Kuriyan J: Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12. Cell 96:425–436, 1999PubMedCrossRefGoogle Scholar
  34. 34.
    Piek E, Heldin CH, Ten Dijke P: Specificity, diversity, and regulation in TGF-beta superfamily signaling. Faseb J 13:2105–2124, 1999PubMedGoogle Scholar
  35. 35.
    Verrecchia F, Mauviel A: Control of connective tissue gene expression by TGF beta: Role of Smad proteins in fibrosis. Curr Rheumatol Rep 4:143–149, 2002PubMedCrossRefGoogle Scholar
  36. 36.
    Sekelsky JJ, Newfeld SJ, Raftery LA, Chartoff EH, Gelbart WM: Genetic characterization and cloning of mothers against dpp, a gene required for decapentaplegic function in Drosophila melanogaster. Genetics 139:1347–1358, 1995PubMedGoogle Scholar
  37. 37.
    Savage C, Das P, Finelli AL, Townsend SR, Sun CY, Baird SE, Padgett RW: Caenorhabditis elegans genes sma-2, sma-3, and sma-4 define a conserved family of transforming growth factor beta pathway components. Proc Natl Acad Sci USA 93:790–794, 1996PubMedCrossRefGoogle Scholar
  38. 38.
    Massague J, Chen YG: Controlling TGF-beta signaling. Genes Dev 14:627–644, 2000PubMedGoogle Scholar
  39. 39.
    Massague J, Wotton D: Transcriptional control by the TGF-beta/Smad signaling system. Embo J 19:1745–1754, 2000PubMedCrossRefGoogle Scholar
  40. 40.
    Verrecchia F, Mauviel A: Transforming growth factor-beta signaling through the Smad pathway: Role in extracellular matrix gene expression and regulation. J Invest Dermatol 118:211–215, 2002PubMedCrossRefGoogle Scholar
  41. 41.
    Asano Y, Ihn H, Yamane K, Jinnin M, Mimura Y, Tamaki K: Phosphatidylinositol 3-kinase is involved in alpha2(I) collagen gene expression in normal and scleroderma fibroblasts. J Immunol 172:7123–7135, 2004PubMedGoogle Scholar
  42. 42.
    Leask A, Abraham DJ: TGF-beta signaling and the fibrotic response. Faseb J 18:816–827, 2004PubMedCrossRefGoogle Scholar
  43. 43.
    Raghow R, Postlethwaite AE, Keski-Oja J, Moses HL, Kang AH: Transforming growth factor-beta increases steady state levels of type I procollagen and fibronectin messenger RNAs posttranscriptionally in cultured human dermal fibroblasts. J Clin Invest 79:1285–1288, 1987PubMedCrossRefGoogle Scholar
  44. 44.
    Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, Heine UI, Liotta LA, Falanga V, Kehrl JH, et al.: Transforming growth factor type beta: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 83:4167–4171, 1986PubMedCrossRefGoogle Scholar
  45. 45.
    Varga J: Scleroderma and Smads: Dysfunctional Smad family dynamics culminating in fibrosis. Arthritis Rheum 46:1703–1713, 2002PubMedCrossRefGoogle Scholar
  46. 46.
    Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M: Increased expression of TGF-beta receptors by scleroderma fibroblasts: Evidence for contribution of autocrine TGF-beta signaling to scleroderma phenotype. J Invest Dermatol 110:47–51, 1998PubMedCrossRefGoogle Scholar
  47. 47.
    Ihn H, Yamane K, Kubo M, Tamaki K: Blockade of endogenous transforming growth factor beta signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: Association with increased expression of transforming growth factor beta receptors. Arthritis Rheum 44:474–480, 2001PubMedCrossRefGoogle Scholar
  48. 48.
    Mori Y, Chen SJ, Varga J: Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum 48:1964–1978, 2003PubMedCrossRefGoogle Scholar
  49. 49.
    Jaffee BD, Claman HN: Chronic graft-versus-host disease (GVHD) as a model for scleroderma. I. Description of model systems. Cell Immunol 77:1–12, 1983PubMedCrossRefGoogle Scholar
  50. 50.
    McCormick LL, Zhang Y, Tootell E, Gilliam AC: Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: A model for human scleroderma. J Immunol 163:5693–5699, 1999PubMedGoogle Scholar
  51. 51.
    Halevy O, Nagler A, Levi-Schaffer F, Genina O, Pines M: Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: Effect of halofuginone. Biochem Pharmacol 52:1057–1063, 1996PubMedCrossRefGoogle Scholar
  52. 52.
    McGaha TL, Phelps RG, Spiera H, Bona C: Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. J Invest Dermatol 118:461–470, 2002PubMedCrossRefGoogle Scholar
  53. 53.
    Lakos G, Takagawa S, Chen SJ, Ferreira AM, Han G, Masuda K, Wang XJ, DiPietro LA, Varga J: Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol 165:203–217, 2004PubMedGoogle Scholar
  54. 54.
    McGaha TL, Kodera T, Spiera H, Stan AC, Pines M, Bona CA: Halofuginone inhibition of COL1A2 promoter activity via a c-Jun-dependent mechanism. Arthritis Rheum 46:2748–2761, 2002PubMedCrossRefGoogle Scholar
  55. 55.
    Philips N, Bashey RI, Jimenez SA: Increased alpha 1(I) procollagen gene expression in tight skin (TSK) mice myocardial fibroblasts is due to a reduced interaction of a negative regulatory sequence with AP-1 transcription factor. J Biol Chem 270:9313–9321, 1995PubMedCrossRefGoogle Scholar
  56. 56.
    McGaha T, Kodera T, Phelps R, Spiera H, Pines M, Bona C: Effect of halofuginone on the development of tight skin (TSK) syndrome. Autoimmunity 35:277–282, 2002PubMedCrossRefGoogle Scholar
  57. 57.
    Brown KD, Zurawski SM, Mosmann TR, Zurawski G: A family of small inducible proteins secreted by leukocytes are members of a new superfamily that includes leukocyte and fibroblast-derived inflammatory agents, growth factors, and indicators of various activation processes. J Immunol 142:679–687, 1989PubMedGoogle Scholar
  58. 58.
    Bendelac A, Rivera MN, Park SH, Roark JH: Mouse CD1-specific NK1 T cells: Development, specificity, and function. Annu Rev Immunol 15:535–562, 1997PubMedCrossRefGoogle Scholar
  59. 59.
    Burd PR, Thompson WC, Max EE, Mills FC: Activated mast cells produce interleukin 13. J Exp Med 181:1373–1380, 1995PubMedCrossRefGoogle Scholar
  60. 60.
    Zurawski G, de Vries JE: Interleukin 13 elicits a subset of the activities of its close relative interleukin 4. Stem Cells 12:169–174, 1994PubMedCrossRefGoogle Scholar
  61. 61.
    Wynn TA: IL-13 effector functions. Annu Rev Immunol 21:425–456, 2003PubMedCrossRefGoogle Scholar
  62. 62.
    Paul WE: Interleukin-4: A prototypic immunoregulatory lymphokine. Blood 77:1859–1870, 1991PubMedGoogle Scholar
  63. 63.
    Lin JX, Migone TS, Tsang M, Friedmann M, Weatherbee JA, Zhou L, Yamauchi A, Bloom ET, Mietz J, John S, et al.: The role of shared receptor motifs and common Stat proteins in the generation of cytokine pleiotropy and redundancy by IL-2, IL-4, IL-7, IL-13, and IL-15. Immunity 2:331–339, 1995PubMedCrossRefGoogle Scholar
  64. 64.
    Donaldson DD, Whitters MJ, Fitz LJ, Neben TY, Finnerty H, Henderson SL, O'Hara RM, Jr., Beier DR, Turner KJ, Wood CR, Collins M: The murine IL-13 receptor alpha 2: Molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1. J Immunol 161:2317–2324, 1998PubMedGoogle Scholar
  65. 65.
    Izuhara K, Shirakawa T: Signal transduction via the interleukin-4 receptor and its correlation with atopy. Int J Mol Med 3:3–10, 1999PubMedGoogle Scholar
  66. 66.
    Murata T, Husain SR, Mohri H, Puri RK: Two different IL-13 receptor chains are expressed in normal human skin fibroblasts, and IL-4 and IL-13 mediate signal transduction through a common pathway. Int Immunol 10:1103–1110, 1998PubMedCrossRefGoogle Scholar
  67. 67.
    Lee KS, Ro YJ, Ryoo YW, Kwon HJ, Song JY: Regulation of interleukin-4 on collagen gene expression by systemic sclerosis fibroblasts in culture. J Dermatol Sci 12:110–117, 1996PubMedCrossRefGoogle Scholar
  68. 68.
    Needleman BW, Wigley FM, Stair RW: Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum 35:67–72, 1992PubMedCrossRefGoogle Scholar
  69. 69.
    Kodera T, McGaha TL, Phelps R, Paul WE, Bona CA: Disrupting the IL-4 gene rescues mice homozygous for the tight-skin mutation from embryonic death and diminishes TGF-beta production by fibroblasts. Proc Natl Acad Sci USA 99:3800–3805, 2002PubMedCrossRefGoogle Scholar
  70. 70.
    McGaha T, Saito S, Phelps RG, Gordon R, Noben-Trauth N, Paul WE, Bona C: Lack of skin fibrosis in tight skin (TSK) mice with targeted mutation in the interleukin-4R alpha and transforming growth factor-beta genes. J Invest Dermatol 116:136–143, 2001PubMedCrossRefGoogle Scholar
  71. 71.
    Ong C, Wong C, Roberts CR, Teh HS, Jirik FR: Anti-IL-4 treatment prevents dermal collagen deposition in the tight-skin mouse model of scleroderma. Eur J Immunol 28:2619–2629, 1998PubMedCrossRefGoogle Scholar
  72. 72.
    Elbe-Burger A, Egyed A, Olt S, Klubal R, Mann U, Rappersberger K, Rot A, Stingl G: Overexpression of IL-4 alters the homeostasis in the skin. J Invest Dermatol 118:767–778, 2002PubMedCrossRefGoogle Scholar
  73. 73.
    McGaha TL, Le M, Kodera T, Stoica C, Zhu J, Paul WE, Bona CA: Molecular mechanisms of interleukin-4-induced up-regulation of type I collagen gene expression in murine fibroblasts. Arthritis Rheum 48:2275–2284, 2003PubMedCrossRefGoogle Scholar
  74. 74.
    Jinnin M, Ihn H, Yamane K, Tamaki K: Interleukin-13 stimulates the transcription of the human alpha2(I) collagen gene in human dermal fibroblasts. J Biol Chem 279:41783–41791, 2004PubMedCrossRefGoogle Scholar
  75. 75.
    Kohyama M, Sugahara D, Hosokawa H, Kubo M, Hozumi N: IL-4-mediated development of TGF-beta1-producing cells from naive CD4(+) T cells through a STAT6-independent mechanism. Eur J Immunol 31:3659–3666, 2001PubMedCrossRefGoogle Scholar
  76. 76.
    Glimcher LH, Singh H: Transcription factors in lymphocyte development—T and B cells get together. Cell 96:13–23, 1999PubMedCrossRefGoogle Scholar
  77. 77.
    Molkentin JD: The zinc finger-containing transcription factors GATA-4, -5, and -6. Ubiquitously expressed regulators of tissue-specific gene expression. J Biol Chem 275:38949–38952, 2000PubMedCrossRefGoogle Scholar
  78. 78.
    Zhu J, Guo L, Watson CJ, Hu-Li J, Paul WE: Stat6 is necessary and sufficient for IL-4's role in Th2 differentiation and cell expansion. J Immunol 66:7276–7281, 2001Google Scholar
  79. 79.
    Uitto J, Bauer EA, Eisen AZ: Scleroderma: Increased biosynthesis of triple-helical type I and type III procollagens associated with unaltered expression of collagenase by skin fibroblasts in culture. J Clin Invest 64:921–930, 1979PubMedCrossRefGoogle Scholar
  80. 80.
    Van Obberghen-Schilling E, Roche NS, Flanders KC, Sporn MB, Roberts AB: Transforming growth factor beta 1 positively regulates its own expression in normal and transformed cells. J Biol Chem 263:7741–7746, 1998Google Scholar
  81. 81.
    Sato M, Shegogue D, Gore EA, Smith EA, McDermott PJ, Trojanowska M: Role of p38 MAPK in transforming growth factor beta stimulation of collagen production by scleroderma and healthy dermal fibroblasts. J Invest Dermatol 118:704–711, 2002PubMedCrossRefGoogle Scholar
  82. 82.
    Quandt K, Frech K, Karas K, Wingender E, Werner T: Mat and MatInspector. New fast and versatile tools for detection of consensus matches in nucleotide sequence data. Nucleic Acid Res 23:4878–4884, 1995PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, Inc. 2005

Authors and Affiliations

  • Rashpal K. Bhogal
    • 1
  • Cristina M. Stoica
    • 1
  • Tracy L. McGaha
    • 2
  • Constantin A. Bona
    • 1
    • 3
  1. 1.Department of MicrobiologyMount Sinai School of MedicineNew York
  2. 2.Laboratory of Molecular Genetics and ImmunologyThe Rockefellar UniversityNew York
  3. 3.Department of MicrobiologyThe Mount Sinai School of MedicineNew York

Personalised recommendations